Featured Content

Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the ...

Daratumumab for Newly Diagnosed Multiple Myeloma

Jesus San Miguel, MD, PhD, discusses his presentation at the ASH 2017 meeting in Atlanta.

Daratumumab Given Subcutaneously for Multiple Myeloma

Ajai Chari, MD, discusses his findings at the ASH 2017 meeting in Atlanta.

Venetoclax Plus Rituximab for Chronic Lymphocytic Leukemia

Gary Gordon, MD, PhD, discusses latest findings at the ASH 2017 meeting in Atlanta.

More Features>>>

Hematologic Cancers Resources

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters